<?xml version="1.0" encoding="UTF-8"?>
<p>However, the LPV/r combination in the treatment of COVID-19 is not justified or, at least, needs further investigations. Cao B and co-workers conducted a randomized, controlled, open-label trial in adult hospitalized patients with COVID-19 to test the efficacy and safety of the oral lopinavir (400 mg) associated with ritonavir (200 mg) in SARS-CoV-2 infection. At the end of their study, there was no evidence that LPV/r combination exerted any significant antiviral effect against SARS-CoV-2, as the viral RNA was still detected in 40.7% of the patients belonging to the LPV/r group [
 <xref rid="B31-jcm-09-02084" ref-type="bibr">31</xref>,
 <xref rid="B112-jcm-09-02084" ref-type="bibr">112</xref>]. Moreover, European Society of Intensive Care Medicine (ESICM) does not currently recommend LPV/r for routine use [
 <xref rid="B31-jcm-09-02084" ref-type="bibr">31</xref>,
 <xref rid="B113-jcm-09-02084" ref-type="bibr">113</xref>].
</p>
